UiPath hits an inflection point with stabilizing SaaS, AI roadmap, Maestro platform upsells, top partnerships, and clean ...

UiPath remains a buy, outperforming the S&P 500 with a 53.6% gain since March 2025, driven by operational turnaround. Click ...

UiPath Inc. (NYSE: PATH) was recently added to the S&P MidCap 400 index, replacing Synovus Financial Corp., reflecting the automation company's increased scale and market presence. This index ...

UiPath Inc. (NYSE:PATH) is one of the AI stocks under $20 to buy now. On December 9, Morgan Stanley analyst Sanjit Singh raised the firm’s price target on UiPath to $19 from $15 with an Equal Weight ...

What To Know: After the market close on Tuesday, S&P Dow Jones Indices announced that agentic automation company UiPath will replace Synovus Financial Corp (NYSE: SNV) in the S&P MidCap 400, effective ...

Figma is challenging Adobe with its lightweight, cloud-based AI design tools. UiPath helps companies automate tasks traditionally performed by human employees with software robots. The slower-growth ...

UiPath, which specializes in robotic process automation software, has been expanding its presence in the enterprise automation market. The addition to the midcap index represents a milestone for the ...

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.

Enzymes help with specific functions that are vital to the operation and overall health of the human body. They help speed up chemical reactions and are essential for respiration, digestion, muscle ...